StreetInsider.com News Articles

Goldman Sachs Starts Prelude Therapeutics (PRLD) at Early-Stage Biotech

Fri, 15 May 2026 05:07:25 -0400

Goldman Sachs analyst Corinne Johnson initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Early-Stage Biotech rating.

The analyst comments "We initiate coverage of Prelude Therapeutics (PRLD) at Early-Stage Biotech. PRLD is a clinical-stage biotech company with a pipeline of candidates focused on innovative medicines for cancers with high unmet needs; its lead programs include highly selective KAT6A degrader (PRT-13722) for metastatic breast cancer (mBC) and mutant-selective JAK2 inhibitor (PRT-12396) for Myeloproliferative Neoplasms (MPNs). We view the key debate for PRLD over the next several years will be whether its KAT6A degrader asset, PRT-13722, will be meaningfully differentiated in a crowded

Goldman Sachs Starts Prelude Therapeutics (PRLD) at Early-Stage Biotech

Fri, 15 May 2026 05:07:25 -0400

Goldman Sachs analyst Corinne Johnson initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Early-Stage Biotech rating.

Goldman Sachs Starts Prelude Therapeutics (PRLD) at Early-Stage Biotech

Fri, 15 May 2026 05:07:25 -0400

Goldman Sachs analyst Corinne Johnson initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Early-Stage Biotech rating.

Goldman Sachs Starts Prelude Therapeutics (PRLD) at Early-Stage Biotech

Fri, 15 May 2026 05:07:25 -0400

Goldman Sachs analyst Corinne Johnson initiates coverage on Prelude Therapeutics (NASDAQ: PRLD) with a Early-Stage Biotech rating.

Prelude Therapeutics (PRLD) PT Raised to $10 at Jefferies

Tue, 12 May 2026 16:02:41 -0400

Jefferies analyst Roger Song raised the price target on Prelude Therapeutics (NASDAQ: PRLD) to $10.00 (from $4.50) while maintaining a Buy rating.

The analyst comments "PRT12396 (JAK2V617F) has entered Ph1 w/ enrollment underway, while FIC KAT6A degrader PRT13722 remains on track for mid ’26 IND w/ Ph1 start in 2H26. Next-gen DAC platform (SMARCA2/4, CDK9) and early mCALR program provide longer-dated upside optionality. B/S materially de-risked post $90M raise, extending runway into 2Q28. Next 12 mos driven by early clinical execution and INCY option value. We increase pipeline and platform from $350M to $500M, PT to $10. Buy."

Prelude Therapeutics (PRLD) PT Raised to $10 at Jefferies

Tue, 12 May 2026 16:02:41 -0400

Jefferies analyst Roger Song raised the price target on Prelude Therapeutics (NASDAQ: PRLD) to $10.00 (from $4.50) while maintaining a Buy rating.

Form 10-Q Prelude Therapeutics For: Mar 31

Tue, 12 May 2026 07:19:00 -0400

si-local-file:///var/storage/secattach/20260512/26472979.html

Form 10-Q Prelude Therapeutics For: Mar 31

Tue, 12 May 2026 07:19:00 -0400

si-local-file:///var/storage/secattach/20260512/26472979.html

Form 8-K Prelude Therapeutics For: May 12

Tue, 12 May 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260512/26472953.html

Form 8-K Prelude Therapeutics For: May 12

Tue, 12 May 2026 07:12:00 -0400

si-local-file:///var/storage/secattach/20260512/26472953.html

Prelude Therapeutics Incorporated (PRLD) Tops Q1 EPS by 10c

Tue, 12 May 2026 07:03:34 -0400

Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q1 EPS of ($0.13), $0.10 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $4.58 million.

For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tue, 12 May 2026 07:01:00 -0400

Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

The Company expects to file the IND for PRT13722, first-in-class highly-selective oral KAT6A degrader, by mid-2026 with Phase 1 study initiation in ER+ breast cancer anticipated in the 2H 2026

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Appointed Charles Morris, M.D. as Chief Medical Officer

Current cash runway expected into second quarter of 2028 based on preliminary